Pictet Asset Management Holding SA Sells 25,732 Shares of Bruker Corporation $BRKR

Pictet Asset Management Holding SA reduced its holdings in Bruker Corporation (NASDAQ:BRKR) by 22.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 89,389 shares of the medical research company’s stock after selling 25,732 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Bruker were worth $3,229,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BRKR. Los Angeles Capital Management LLC bought a new stake in shares of Bruker during the 4th quarter valued at $26,000. Allworth Financial LP boosted its position in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the period. Summit Securities Group LLC acquired a new stake in shares of Bruker during the fourth quarter worth $50,000. Finally, Covestor Ltd increased its holdings in Bruker by 304.6% in the fourth quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 1,066 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Wall Street Analyst Weigh In

BRKR has been the topic of several analyst reports. Citigroup increased their target price on Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Barclays increased their price target on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price objective on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. TD Cowen boosted their price objective on shares of Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a report on Thursday, May 7th. Finally, Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Bruker presently has a consensus rating of “Hold” and a consensus price target of $54.54.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. The trade was a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 27.20% of the company’s stock.

Bruker Price Performance

NASDAQ BRKR opened at $61.64 on Friday. The business has a 50 day simple moving average of $50.57 and a 200 day simple moving average of $45.02. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The stock has a market cap of $9.38 billion, a price-to-earnings ratio of -256.83, a PEG ratio of 1.97 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. During the same quarter in the previous year, the firm posted $0.47 earnings per share. The business’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.